

Acquisition of own shares

Brussels (Belgium), 24 April 2026 – 20:00 (CEST) – Regulated information

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ("UCB" or the "Company") (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2026.

Under this program, UCB has requested a financial intermediary to repurchase up to 500,000 UCB shares on its behalf under the terms of a discretionary mandate agreement effective as from 16 March 2026 and with initial validity until the later of 30 June 2026, and, to the extent authorized by the extraordinary shareholders' meeting of April 2026, 30 September 2026, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2026, UCB repurchased 102,503 UCB shares on Euronext Brussels in the period from 17 April 2026 up to and including 23 April 2026, as follows:

Date of repurchase	Number of shares	Average Price Paid	Total	Lowest Price Paid	Highest Price Paid
17 April 2026	24.722	262,08 €	6.479.173,90 €	256,50 €	263,90 €
20 April 2026	21.452	257,05 €	5.514.217,29 €	253,90 €	260,30 €
21 April 2026	26.228	249,35 €	6.539.860,00 €	247,10 €	259,00 €
22 April 2026	24.901	242,96 €	6.050.034,11 €	240,30 €	247,70 €
23 April 2026	5.200	246,40 €	1.281.273,76 €	240,80 €	248,60 €

As a result, the Share Repurchase Program 2026 has been completed.

This press release is available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations

Antje Witte
T +32 2 559 94 14
Antje.Witte@ucb.com

Yvonne Naughton
T: +44-7566790245
yvonne.naughton@ucb.com



UCB News

Sahar Yazdian
T: +32.2.559.9137
<mailto:sahar.yazdian@ucb.com>

Corporate Communications
Laurent Schöts
T+32 2 559 92 64
<mailto:laurent.schots@ucb.com>

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).